Advertisement

Topics

Adamis Pharmaceuticals (ADMP) Skyrockets 53% On FDA Approval

10:32 EDT 17 Jun 2017 | BiotechPickList

On Thursday, Adamis Pharmaceuticals (NASDAQ:ADMP) skyrocketed to a one-year high of 53% after the company’s allergic reaction treatment gained FDA approval. Adamis announced approval for the pre-filled Epinephrine drug known as Symjepi. The reason why the approval was so significant… Continue Reading

Original Article: Adamis Pharmaceuticals (ADMP) Skyrockets 53% On FDA Approval

NEXT ARTICLE

More From BioPortfolio on "Adamis Pharmaceuticals (ADMP) Skyrockets 53% On FDA Approval"

Advertisement
Quick Search
Advertisement
Advertisement